Trial Scout

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Study Location

Southtowns Gastroenterology

ClinicalTrials.gov Identifier: NCT03259308
Recruitment Status: Recruiting
First Posted: 8/23/2017 12:00:00 AM
Last Update Posted: 5/6/2019 12:00:00 AM

Study Description

Eligibility Criteria

Additional Contacts

Brief Summary

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Condition or Disease

Colitis
Colitis, Ulcerative
Ulcer

Intervention/Treatment

Drug: SHP647 / 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Phase

Phase 3

Detailed Description

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Go to ClinicalTrials.gov >